Moreover, our findings concurred with previous reports that NFKB1 is involved in resistance to chemotherapy and radiotherapy46, indicating that NFKB1 and SMARCC1 could be potential biomarkers for GC diagnosis and for selection of an effective treatment strategy. This evidence concerns the gene SMARCC1 and gastric cancer.